Skip to main content
. 2022 Mar 11;27(4):255–265. doi: 10.1093/oncolo/oyac022

Figure 2.

Figure 2.

Time-to-treatment failure (A, B) and OS (C, D) in patients who received afatinib according to uncommon mutation category. Time-to-treatment failure (E, F) and OS (G, H) in patients who received a first-generation EGFR TKI according to uncommon mutation category.